Liver glycogenosis as early manifestation in type 1 diabetes mellitus

L Carcione1, F Lombardo, M F Messina

  • 1Department of Pediatrics, University of Messina, Messina, Italy.

Diabetes, Nutrition & Metabolism
|November 26, 2003
PubMed

Insights

Hepatic glycogenosis, a liver condition, can manifest during Type 1 diabetes mellitus (T1DM) onset or early treatment. This occurs due to high blood sugar and insulin therapy, resolving with improved diabetes control.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Hepatology

Background:

  • Type 1 diabetes mellitus (T1DM) presentation in children typically involves metabolic derangements, not liver dysfunction.
  • Hepatic glycogenosis is characterized by excessive glycogen accumulation in liver cells.

Observation:

  • Two pediatric cases presented with clinical and biochemical signs of hepatic glycogenosis at T1DM onset.
  • Liver abnormalities (hepatomegaly, elevated aminotransferases) appeared days after initiating insulin therapy, not at T1DM diagnosis.
  • Initial liver function and dimensions were normal despite severe hyperglycemia at T1DM onset.

Findings:

  • Hepatic glycogenosis developed during T1DM treatment, linked to supraphysiological insulin doses and hyperglycemia.
  • Patients experienced complete physical and biochemical recovery within weeks of improved glycemic control.
  • This suggests hepatic glycogenosis can be an early, albeit uncommon, manifestation of T1DM.

Implications:

  • Clinicians should consider hepatic glycogenosis in children with T1DM, particularly during initial intensive insulin therapy.
  • Recognizing this association aids in accurate diagnosis and management of T1DM complications.
  • Further research is needed to understand the prevalence and mechanisms of T1DM-associated hepatic glycogenosis.

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...